Results 241 to 250 of about 2,385,197 (304)

LINC00892 inhibits hepatocellular carcinoma progression through SBDS/EIF6‐mediated ribosomal stress and interacting with the immune microenvironment

VIEW, EarlyView.
LINC00892 is lowly expressed in HCC. LINC00892 overexpression induces ribosomal stress via inhibiting SBDS, restrains EIF6 nuclear translocation and activates p53 pathway. LINC00892 overexpression and p53 activation jointly suppress HCC progression. High LINC00892 is associted with infiltration of CD8+ T cells, B cells and macrophages, and associated ...
Xu Zhang, Lina Ma, Juan Ma, Long Hai, Lina Wu, Xueyan Feng, Xiangchun Ding   +6 more
wiley   +1 more source

Correction: The impact of ageing on the distribution of preformed anti-HLA and anti-MICA antibody specificities in recipients from eastern China prior to initial HSCT. [PDF]

Immun Ageing
Pan Q, Ma X, You Y, Yu Y, Fan S, Wang X, Wang M, Gao M, Gong G, Miao K, Shen J, Zhou X.   +11 more
europepmc   +1 more source

In Vitro and In Vivo Immunomodulatory and Protective Effects of Leukemia Inhibitory Factor‐Engineered Mesenchymal Stromal Cells in Experimental Endotoxemia

Microbiology and Immunology, EarlyView.
ABSTRACT Sepsis is a life‐threatening condition characterized by dysregulated systemic inflammation and high mortality rates. Mesenchymal stem/stromal cells (MSCs) have emerged as promising immunomodulatory agents; however, genetic engineering strategies can enhance their therapeutic efficacy.
Alana Costa de Oliveira, Diego de Carvalho Carneiro, Luiza Carolina França Opretzka, Breno Cardim Barreto, Dahara Keyse Carvalho Silva, Girlaine Café Santos, Cássio Santana Meira, Milena Botelho Pereira Soares   +7 more
wiley   +1 more source

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

Asia-Pacific Journal of Clinical Oncology, EarlyView.
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija, Fiona Kerr, Hazel Gough, Johnathan Soggee, Laurence C. Cheung, Rishi S. Kotecha, Shanti Ramachandran   +6 more
wiley   +1 more source

Combined Use of Tocilizumab and Mesenchymal Stem Cells Attenuate the Development of an Anti-HLA-A2.1 Antibody in a Highly Sensitized Mouse Model. [PDF]

Int J Mol Sci
Fang X, Cui S, Lee H, Min JW, Lim SW, Oh EJ, Yang CW, Shin YJ, Chung BH.   +8 more
europepmc   +1 more source

Pre-transplant crossmatch-negative donor-specific anti-HLA antibody predicts acute antibody-mediated rejection but not long-term outcomes in kidney transplantation: an analysis of the Korean Organ Transplantation Registry. [PDF]

Front Immunol
Lee H, Lee H, Sun IO, Park JH, Park JW, Ban TH, Yang J, Kim MS, Yang CW, Chung BH, Korean Organ Transplantation Registry Study Group.   +10 more
europepmc   +1 more source

Donor specific anti-HLA antibodies in hematopoietic stem cell transplantation. Single Center prospective evaluation and desensitization strategies employed. [PDF]

Blood Transfus
La Rocca U, Perrone MP, Piciocchi A, Barberi W, Gesuiti P, Laurenti L, Cinti P, Gozzer M, Bafti MS, Carmini D, Cinelli N, Cavallari C, Giovannetti G, Ricci R, Girelli G, Foà R, Martelli M, Coluzzi S, Iori AP.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pretransplant Anti-HLA-Cw and Anti-HLA-DP Antibodies in Sensitized Patients

Human Immunology, 2012
We investigated the prevalence and the strength of anti-HLA-Cw and DP antibodies and clinical outcomes in kidney transplant recipients with isolated donor-specific anti-HLA-Cw antibodies. Patients on the waiting list were screened by Luminex single antigen beads (One Lambda). The strength of antibodies was determined by mean fluorescence intensity (MFI)
Liise K Kayler, Kwaku Marfo, Graciela de Boccardo   +2 more
exaly   +3 more sources

Platelet transfusion refractoriness and anti‐HLA immunization

Transfusion, 2021
AbstractPlatelet transfusion refractoriness (PTR), defined as an unsatisfactory post‐transfusion platelet count increment, is a common complication of patients receiving multiple transfusions. Different strategies are described in the management of PTR. In this work, we demonstrate the efficacy of the detection and identification of anti‐HLA antibodies
Blandin, Lucie, Dougé, Aurore, Fayard, Amandine, Bay, Jacques‐olivier, Berlie, Guillaume, Pereira, Bruno, Lemal, Richard, Rouzaire, Paul   +7 more
openaire   +2 more sources

Renal Transplantation After Removal of Anti-HLA Antibodies.

Lancet, The, 1984
O N Fernando, J F Moorhead, Z Varghese
exaly   +3 more sources